Corresponding Author: Jeannette Guarner, MD, Emory Medical Laboratories, Emory University Hospital-Midtown Core Laboratory, Emory University School of Medicine, 1364 Clifton Rd, Atlanta, GA 30322 (jguarne@emory.edu).
Published Online: March 27, 2020. doi:10.1001/jama.2020.4940
Conflict of Interest Disclosures: Dr Roback reports being a member of the American Red Cross Biomedical Services Medical Advisory Council; a consultant to CSL Plasma; a consultant to Secure Transfusion Services; and a cofounder, stockholder, and consultant to Cambium Medical Technologies. Dr Guarner reports no disclosures.
1.Shen
C , Wang
Z , Zhao
F ,
et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma.
JAMA... Published online March 27, 2020 doi:
10.1001/jama.2020.4783Google Scholar 5.Kraft
CS , Hewlett
AL , Koepsell
S ,
et al; Nebraska Biocontainment Unit and the Emory Serious Communicable Diseases Unit. The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United States.
Clin Infect Dis. 2015;61(4):496-502. doi:
10.1093/cid/civ334PubMedGoogle ScholarCrossref 6.Dean
CL , Hooper
JW , Dye
JM ,
et al. Characterization of Ebola convalescent plasma donor immune response and psoralen treated plasma in the United States.
Transfusion. 2020. doi:
10.1111/trf.15739PubMedGoogle Scholar